here is how is ee it folkzzz ~~~ FDA's MAIN concern is lack of people in the study -- and comparable drugs its new to them as well so they called insufficient -- and extend it for us and them since then, they have fast track the approval date and approved the plant --- those are good signs -- not bad IMHO